Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHM 703: Crit Care/Heme/Onc > Onco 2: Lymphohohohoma > Flashcards

Onco 2: Lymphohohohoma Flashcards

(50 cards)

Start Studying
1
Q

risk factors for lympohma

A
  1. male
  2. older age (and younger agen in hodgkiins)
  3. immunosuppression
  4. enovironmental
  5. radiaiton
  6. infections (Epstein and HIV)

numbered for footnote, not in order

  • 3, 4, 5 esp in DLBCL
  • 6 esp in Hodgkin’s
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

B symptoms

A

seen in 30% of all B cell lympohomas
- fever
- wt loss (10% over 6 months)
- nigh sweats

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Diffuse large B cell (DLBCL) relapse

A
  • even though it’s curable, it’s so aggressive, high chance of relapse
  • CAR-T
  • BsAb (bispecifc Ab)
  • autologous stem cell transplant
  • salvage chemo
    - R-ICE
    - GDP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

R-ICE

A
  • Rituximab
  • Ifosfamide
  • Carboplatin
  • Etoposide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GDP

A
  • Gemcitabine
  • Dexamethasonne
  • carboPlatin

refractory - salvage chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

DLBCL presentaiton

A
  • B symptoms
  • nodal mass
  • elevated lactate dehydrogease
  • bone marrow involvement
  • AMS
  • laboratory abnoralities: SCr, uric acid, LFTs, electolytes

ympoh nodes lysing (can lead to TLS) -> the dehydrogenase and alb abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

DLBCL dx

A

lympoh node bioposy
- IHC panel to look for ccertain mutations: for non-Hodgkin’s, CD20 is important
- imaging (PET scan) to fiure out what to biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

DLBCL prognosis

A

use the IPI (international prognosis index)
- low score = high risk -> poorer outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

DLBCL treatment

standard treatment (does not include the ifs: EF, CNS, frail)

A
  • preferred: R-CHOP or pola-R-CHP
  • other: DA-R-EPOCH

  • no difference between pola-R-CHP and R-CHOP except that pola may be better for pts with subtype ABC
  • DA-R-EPOCH preferred in more aggressive lympohomas: CMAC, BCL2 and BCL6
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

DLBCL treatment in pts with EF < 40%

A

canNOT receive doxorubucin at regular dose/infusion/formulation
- DA-R-EPOCH: slower infusion -> less cardiotox
- R-CDOP: liposomal doxorubicin instead of regular
- R-CEOP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DLBCL treatment in frail pts or pts > 80

A
  • R-mini-CHOP
  • R-CDOP
  • R-CEOP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DLBCL treatment in pts with parenchymal presnetiaton

A

R-CHOP + high dose MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

DLBCL treatment in pts iwth leptomenigeal presentaiton

A

intrathecal MTX/cytarabine

OR R-CHOP with high dose MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

R-CHOP

A
  • Rituxima
  • Cyclophosphamide
  • Hdryoxydaunorubicin (doxorubicin)
  • Ocovin (vincristine)
  • Prednisone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pola-R-CHP

A
  • Polatuzumab vedotin
  • Rituximab
  • Cyclophosphamide
  • Hdryoxydaunorubicin (doxorubicin)
  • Prednisone

NO vincrisitne dt severe neuropathy risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

DA-R-EPOCH

A
  • Dose Adjusted
  • Rrituximab
  • Etoposide
  • Cyclosphosphamide
  • Hdryoxydaunorubicin (doxorubicin)
  • Ocovin (vincristine)
  • Prednisone

give G-CSF ppx dt febrile neutorpenia risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

R-CDOP

A
  • Rituxima
  • Cyclophosphamide
  • Doxorubicin (liposomal)
  • Ocovin (vincristine)
  • Prednisone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

R-CEOP

A
  • Rituxima
  • Cyclophosphamide
  • Etoposide
  • Ocovin (vincristine)
  • Prednisone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

R-CEPP

A
  • Rituxima
  • Cyclophosphamide
  • Etoposide
  • Prednisone
  • Procarbazine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what makes DA-R-EPOCH “dose adjusted”

A

twice weekly labs
- ANC and plts too high icrease dose
- ANC and plts too low, decrease dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

why did R-CHOP become the mainstay isntad of CHOP

Study These Flashcards
A

MiNT trial: rituxuimab improves surival vs CHOP wihtout increasing tox

22
Q

R-CHOP overall ADR

Study These Flashcards
A
  • high emetic risk
  • moderate febrile neutropenia risk (consdier G-CSF)
  • infections
  • fattigue
  • anemia, neutropenia, thromboctyopenia
  • alopecia
23
Q

doxorubicin ADR

Study These Flashcards
A

cardiotox -> max lifetime dose

24
Q

vincristine ADR

Study These Flashcards
A
  • peripheral neuropathy: max dose 2mg
  • constipation
25
cyclosphosphamdie ADR
hemorrhagic cystitis (though this is unlikely at CHOP dose)
26
rituximab MOA
anti-CD20
27
rituximab ADR
- infusion relataed rxn -> premiedicae and give first dose over 6 hrs (if well tolerated can give susbequent doses in like 60-90min) - HepB reactivation - hypergammaglobinuemia (B cell depletion) - consider holdign for first cycle if lyphoma in GI tract dt perforation - progressive multifocal leukoencephalopathy
28
when to give entavacir in pts receiving rituximab
if pt has chronic HepB - HBsAg (+) and antiHBC (+)
29
polatuzmab MOA
antiCD79B antibody-drug (vedotin) complex - mab directly delivers drug to tumor
30
polatuzumab ADR
- constsipation - skeletomuscular pain - peripheral neuropathy - infusion reaction - anemia, neutropenia, thrombocytopenia
31
CLL/SLL
accumulation of immunologically dysfunctional mature B lympohcytes - up to 50% pts do NOT need treatment
32
CLL/SLL sympotms
only 30% of pts symptomatic - enlarged lympoh nodes - enlarged spleen or liver - B symptoms - autoimmune cytopenia; hemolytic anemia or ITP - hypergamaglobinemia -> frequent infeciotsn
33
CLL/SLL prognosis factors
unfavorable outcomes if - del(17p) - Tp53 mutation
34
who gets treatment in CLL/SLL
- sympotomatic: B sympoms - end organ damage - progression of bulky disease: splenomegaly or lypohadenopathy - bone marrow failure: anemia, thrombocytopenia - disease outside of lymph ndes
35
CLL/SLL treatment: of pts who are getting treatment, who gets fixed duration adn who gets indefinite and what's the treatment
- indefiite: elderly, poor performing, pt preference - (acalabrutinib +/- obinutuzumab) OR (zanubrutinib) - fixd duraiton: younger, good performing (no comorbidites, no renal impairment - venetoclax + obinutuzumab
36
Obinutuzumab MOA
2nd gen antiCD-20 (lil more potent than rituximab) - Ab dependent cellular cytotox - complement dependent cytotox - Ab dependent phagocytosis - activation of lysosomes -> cell death
37
Obinutuzumab ADR
- infusion reaction -> titration schedule for first cucle and pre-medicate - Hep B reactivation - chekc panel prior to start - incrased risk of viral infectionN: acyclovir ppx
38
BTKi MOA
bruton tyrosine kinase inhibitors - bind to BTK enzyme -> prevent BCR sgnaling - prevent proliferation and surivval of malignant nad normal cells ## Footnote on initiation may have transient increase in lympohcyte count -> does NOT mean disease progression
39
BTKi ADR | by agent
- ibrutinib: neutropenia, afib, HTN, bleed, diarrhea - acalabrutinib: HA and musculosketela pain (self resolving, APAP and NSAIDs prn) - zanubrutinib: neutropenia (and *least* likely to cause afib)
40
classical Hodgkin's presentaiton
presence of mature B cells with 2 nuclei (Reed-Sternberg cells) - B sympotoms - lymphadenopathy - lympoh node biopsy (+) for CD30+ - gneralize malaise: cough, SOB, decreased appetite
41
classical Hodgkin's treatment | cHL
goal is cure - stage I/II (whether or not favorable or bulky: ABVD - stage III/IV: ABVD or BV+AVD
42
ABVD
- **A**driamycin (**doxorubicin**) - **B**leomycin - **V**in*blast*ine - **D**acarbazine
43
BV-AVD
- **B**rentuximab **V**edotin - **A**driamycin (**doxorubicin**) - **V**inblastine - **D**acarbazine | no bleomycin dt pulm tox
44
ABVD general ADR
- high emetic risk -> high anti-emetic ppx - infection - fatigue - anemia, neutropenia, thrombocytopenia - alopecia
45
bleomycin ADR
pulm tox - avoid G-CSF despite some febrile neutropenia risk for ABVD; if pt at high risk for recurrence, can dc bleomycin and do G-CSF | can also dc bleomycin if pt doing well? we want to use lowest dose
46
dacarbizine ADR
cytopenias
47
brentuximab vedotin MOA
antiCD30 Ab-drug conjugate
48
brentuximab vedotin ADR
- peripheral neuroapthy - infusion rxn - anemia, neutropenia, thrombocytopenia - pulm tox - constipation | MUST give with G-CSF (febrile neutropenia risk?)
49
non-Hodgkin's relapse/refractory treatment | DLBCL
typically occurs within 3 yrs - salvage chemo: R-ICE OR GVD - autologous stem cell transplant - immunotherapy (can add to salvage therapy): nivolumbab or pembrolizumab
50
GVD
- **G**emcitabine - **V**inorelbine - **D**oxorubicin (*lipsomal*)

PHM 703: Crit Care/Heme/Onc (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions